Charles River links with Distributed Bio to advance antibody discovery platform

monoclonal antibodies
Charles River has inked a partnership deal with Distributed Bio for access to antibody libraries and integrated antibody optimization technologies. (Novasep)

Charles River has inked a partnership deal with Distributed Bio that will give the CRO’s clients access to antibody libraries and integrated antibody optimization technologies.

Under the agreement, the two companies aim to create an end-to-end platform for therapeutic antibody discovery and development, they said.

San Francisco-based Distributed Bio provides computationally optimized libraries that can generate more than 5,000 unique hits against every antigen tested. Its platform can speed the discovery process to 3 to 4 months, it said.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Distributed Bio’s technology, coupled with Charles River’s deep scientific strength in drug discovery and early-stage development, ensure that our portfolio is truly next generation,” Birgit Girshick, Charles River’s EVP of Discovery and Safety, said in a statement. “This combination provides our clients with Distributed Bio’s ability to discover new antibodies, then proceed seamlessly from hit to clinical candidate faster than before.”

Earlier this year, in two separate agreements, Pfizer and Boehringer Ingelheim signed agreements for drug discovery using Distributed Bio’s library Super Human 2.0.

Suggested Articles

Scott Gottlieb has slipped right back into his old ways, becoming "special partner" at his old life science VC firm New Enterprise Associates.

Novartis, Otsuka, Pfizer and Sanofi will use technology from Verily’s Project Baseline to carry out clinical studies in various disease areas.

Biotech-CRO hybrid Evotec is continuing its buying and collaborating strategy with its acquisition of U.S. biologics company Just Biotherapeutics.